Acutis Biosciences
The AI engine Fit Assessment
BetaAcutis Biosciences leverages machine learning for biomarker discovery and supports the development of new therapeutics, enhancing precision medicine.
Blurb
HQ Location
Founded
Employees
Total funding raised
Last Funding Event
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
- Biomarker Identification
Acutis Biosciences is a subsidiary Contract Research Organization (CRO) under the ownership of Acutis.
At Acutis Biosciences, we are reimagining biomarker discovery at the intersection of DNA, RNA, and protein diagnostics, and rewriting the rules to champion our biopharma partners. Our focus isn't just pioneering drug discovery and development; it's also forging an era of service excellence, setting a new standard in the industry to elevate precision medicine to another level.
We specialize in enabling biopharmaceutical companies to discover biomarkers through advanced multi-omics analysis solutions powered by machine learning (ML) and artificial intelligence (AI). Our technology platforms in genomics and histopathology support our partners in development and validation of state-of-the-art cancer molecular diagnostic assays, in oncology, immuno-oncology and infectious diseases.
Leading pharmaceutical and biotech companies trust us to deliver 11-star service coupled to extraordinary science.
Learn more: www.acutisbiosciences.com